Filing Flows › Comparisons › BBNX vs DCTH
Beta Bionics vs Delcath Systems: BBNX and DCTH compared
Beta Bionics is the larger company: $35.5M of revenue in its latest quarter (Q3 2026) against $35.1M for Delcath Systems (Q3 2026). Delcath Systems is growing faster (+71% against +30% a year earlier). Delcath Systems is more profitable, with an operating margin of 20.3% against -74.9%.
Where the money goes: BBNX and DCTH
Beta Bionics (BBNX) · Q3 2026
Beta Bionics, Q3 2026: revenue $35.5M (+30% year over year), operating margin -74.9%, net loss $24.4M, operating cash flow −$12.3M. The chart follows the revenue to costs, profit and cash.
Delcath Systems (DCTH) · Q3 2026
Delcath Systems, Q3 2026: revenue $35.1M (+71% year over year), operating margin 20.3%, net earnings $7.0M, operating cash flow $8.2M. The chart follows the revenue to costs, profit and cash.
| Beta Bionics (BBNX) | Delcath Systems (DCTH) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $35.5M | $35.1M |
| Revenue growth, Y/Y | +30% | +71% |
| Gross margin | — | 88.8% |
| Operating margin | -74.9% | 20.3% |
| Net earnings | −$24.4M | $7.0M |
| Net margin | -68.6% | 19.8% |
| Operating cash flow | −$12.3M | $8.2M |
| Free cash flow | — | $6.9M |
Where the revenue comes from
Delcath Systems
- HEPZATO KIT: $32.7M (93%)
- CHEMOSAT: $2.4M (7%)
Questions
Which is bigger, Beta Bionics or Delcath Systems?
Beta Bionics is the larger company: $35.5M of revenue in its latest quarter (Q3 2026) against $35.1M for Delcath Systems (Q3 2026).
Is Beta Bionics or Delcath Systems growing faster?
Delcath Systems is growing faster (+71% against +30% a year earlier).
Which is more profitable, Beta Bionics or Delcath Systems?
Delcath Systems is more profitable, with an operating margin of 20.3% against -74.9%.
More: Beta Bionics earnings · how Beta Bionics makes money · Delcath Systems earnings · how Delcath Systems makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 27, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.